127 related articles for article (PubMed ID: 20737546)
1. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.
Naumann M; Carruthers A; Carruthers J; Aurora SK; Zafonte R; Abu-Shakra S; Boodhoo T; Miller-Messana MA; Demos G; James L; Beddingfield F; VanDenburgh A; Chapman MA; Brin MF
Mov Disord; 2010 Oct; 25(13):2211-8. PubMed ID: 20737546
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia.
Charles D; Brashear A; Hauser RA; Li HI; Boo LM; Brin MF;
Clin Neuropharmacol; 2012; 35(5):208-14. PubMed ID: 22948497
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX
Jankovic J; Carruthers J; Naumann M; Ogilvie P; Boodhoo T; Attar M; Gupta S; Singh R; Soliman J; Yushmanova I; Brin MF; Shen J
Toxins (Basel); 2023 May; 15(5):. PubMed ID: 37235376
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A.
Lawrence I; Moy R
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S66-71. PubMed ID: 19945007
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
Brin MF; Comella CL; Jankovic J; Lai F; Naumann M;
Mov Disord; 2008 Jul; 23(10):1353-60. PubMed ID: 18546321
[TBL] [Abstract][Full Text] [Related]
6. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
Yablon SA; Brashear A; Gordon MF; Elovic EP; Turkel CC; Daggett S; Liu J; Brin MF
Clin Ther; 2007 Apr; 29(4):683-90. PubMed ID: 17617291
[TBL] [Abstract][Full Text] [Related]
7. Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis.
Yablon SA; Brin MF; VanDenburgh AM; Zhou J; Garabedian-Ruffalo SM; Abu-Shakra S; Beddingfield FC
Mov Disord; 2011 Feb; 26(2):209-15. PubMed ID: 20960474
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
Naumann M; Lowe NJ; Kumar CR; Hamm H;
Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.
Dmochowski R; Chapple C; Nitti VW; Chancellor M; Everaert K; Thompson C; Daniell G; Zhou J; Haag-Molkenteller C
J Urol; 2010 Dec; 184(6):2416-22. PubMed ID: 20952013
[TBL] [Abstract][Full Text] [Related]
10. Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.
Coleman C; Hubble J; Schwab J; Beffy JL; Picaut P; Morte C
Int J Neurosci; 2012 Jul; 122(7):358-62. PubMed ID: 22356470
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin: examining duration of effect in facial aesthetic applications.
Flynn TC
Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
14. Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment.
Jog M; Wein T; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
Can J Neurol Sci; 2016 Sep; 43(5):687-96. PubMed ID: 27430524
[TBL] [Abstract][Full Text] [Related]
15. OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines.
Glogau R; Kane M; Beddingfield F; Somogyi C; Lei X; Caulkins C; Gallagher C
Dermatol Surg; 2012 Nov; 38(11):1794-803. PubMed ID: 23106853
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
17. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
19. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
[TBL] [Abstract][Full Text] [Related]
20. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
